ResearcherUniversity of WrocławNo recent work listed
Agnieszka Gizak
Matched on ORCID iD 0000-0001-9367-0270; OpenAlex author ID A5038928679. Sources: OpenAlex.
Their work
- Papers
- 9 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2018: 1 paper · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper · 2022: 3 papers
Papers 9
- Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1… Last author DOI 10.18632/aging.204038↗
- APR-246-The Mutant TP53 Reactivator-Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Proliferation of Pancreatic Cancer Cells. Co-author DOI 10.3390/biom12020276↗
- Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53. Co-author DOI 10.3390/cells11050794↗
- Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53. Co-author DOI 10.1016/j.jbior.2020.100780↗
- Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic c… Co-author DOI 10.1016/j.jbior.2019.100672↗
- Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. Co-author DOI 10.1016/j.jbior.2018.10.003↗
- Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutrac… Co-author DOI 10.1016/j.jbior.2019.03.002↗
- Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. Co-author DOI 10.1016/j.jbior.2019.04.003↗
- Metformin influences drug sensitivity in pancreatic cancer cells. Co-author DOI 10.1016/j.jbior.2018.02.002↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Stephen Lee Abrams · 9 shared papers, 2018–2022 · strength 0.91
- Paper APR-246-The Mutant TP53 Reactivator-Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Pro… DOI 10.3390/biom12020276↗
- Paper Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic … DOI 10.18632/aging.204038↗
- Paper Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence an… DOI 10.3390/cells11050794↗
- James Andrew McCubrey · 9 shared papers, 2018–2022 · strength 0.91
- Paper APR-246-The Mutant TP53 Reactivator-Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Pro… DOI 10.3390/biom12020276↗
- Paper Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic … DOI 10.18632/aging.204038↗
- Paper Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence an… DOI 10.3390/cells11050794↗
- Melchiorre Cervello · 7 shared papers, 2018–2022 · strength 0.61
- Paper Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence an… DOI 10.3390/cells11050794↗
- Paper Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can… DOI 10.1016/j.jbior.2020.100780↗
- Paper Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and… DOI 10.1016/j.jbior.2019.100672↗
- Shaw M. Akula · 6 shared papers, 2019–2022 · strength 0.61
- Paper Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic … DOI 10.18632/aging.204038↗
- Paper Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence an… DOI 10.3390/cells11050794↗
- Paper Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can… DOI 10.1016/j.jbior.2020.100780↗
- Saverio Candido · 6 shared papers, 2018–2021 · strength 0.48
- Paper Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can… DOI 10.1016/j.jbior.2020.100780↗
- Paper Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and… DOI 10.1016/j.jbior.2019.100672↗
- Paper Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. DOI 10.1016/j.jbior.2018.10.003↗
- Przemysław Duda · 3 shared papers, 2022 · strength 0.43
- Paper APR-246-The Mutant TP53 Reactivator-Increases the Effectiveness of Berberine and Modified Berberines to Inhibit the Pro… DOI 10.3390/biom12020276↗
- Paper Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic … DOI 10.18632/aging.204038↗
- Paper Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence an… DOI 10.3390/cells11050794↗
- Marco Falasca · 1 shared paper, 2020 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.